Loading
This study tests a PARP inhibitor; the registry reports that it is active not recruiting.
The registry lists NCT07336446 as active not recruiting, last updated 2026-10-02. Enrolment is 6 actual participants. Interventions: AZD9750, AZD5305. Primary measures include Number of participants with dose-limiting toxicity (DLT), as defined in the protocol (Part A only); Number of participants with Adverse Events and Serious Adverse Events. No results are posted in the registry; this does not exclude separate publications.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Saruparib, PARP, AstraZeneca, Prostate cancer.
Shares Saruparib, PARP, AstraZeneca, Prostate cancer.
Shares Saruparib, PARP, Prostate cancer.
Shares Saruparib, PARP, Prostate cancer.
Shares Saruparib, PARP, AstraZeneca.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/